Vega Therapeutics, Inc

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, blood platelet disease, coagulation protein disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, von Willebrand disease (hereditary or acquired)	Recruiting	Phase 3	2026-09-14		NCT07115004
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, blood platelet disease, cardiovascular disorder, coagulation protein disease, hematologic disorder, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder, vascular disorder, vascular hemostatic disease, von Willebrand disease (hereditary or acquired)	Recruiting	Phase 1 / Phase 2	2025-08-26		NCT05776069

Clinical trials